TheEdgeResearch
Home / Stocks / SRDX

Surmodics, Inc. (SRDX)

NASDAQ Healthcare Medical - Devices
$42.98 ▲ +0.35%
Market Cap
$614.5M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.39
52-Wk Range
25.87-43.0048
CEO
Gary R. Maharaj
Country
US
Currency
USD

Surmodics, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Eden Prairie, MN, US. The stock last traded at $42.98, up 0.35% on the session, giving a market capitalisation of $614.5M. On trailing twelve-month figures it carries a trailing P/E of -58.88, a net margin of -18.3%. Its beta of 1.39 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-58.88
Price / Sales
10.66
Price / Book
5.51
EV / EBITDA
-67.10
Gross margin
71.5%
Operating margin
-16.0%
Net margin
-18.3%
Return on equity
Debt / equity
0.29
Current ratio
3.91
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
389
IPO date
1998-03-04
Headquarters
Eden Prairie, MN, US
About Surmodics, Inc.

Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility, maneuverability, and reliable deployment of medical devices. This segment also develops drug-delivery coating systems, enabling precise, localized therapeutic release directly from a device's surface for applications in various areas, including coronary, peripheral, neuro-vascular, and structural heart procedures. Moreover, this division is involved in the design, development, and manufacturing of interventional medical instruments, notably balloons and catheters, including drug-coated balloons utilized in the treatment of peripheral arterial disease and other conditions. The IVD segment focuses on creating and producing foundational component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. Its portfolio in this area includes protein stabilization reagents, specialized substrates, surface coatings, and antigens. Surmodics was established in 1979 and maintains its corporate headquarters in Eden Prairie, Minnesota.

Comparable companies

Surmodics, Inc. is most often compared with the following Healthcare names:

BVSCBLLCCRNKIDSLABRXSTSMLRTCMDTMCIXOMA
More research on SRDX
SRDX technical analysis SRDX TheEdge Score Compare against peers
Open full interactive analysis & DCF →